Evidence map›Paper›PMID 35974224›Full record

Observational studyClinical rheumatology2022

Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry.

Mari Kihara, Takahiko Sugihara, Junichi Asano, Midori Sato, Hiroshi Kaneko, Sei Muraoka, Shiro Ohshima, Toshihiro Nanki

Open access · bronzeAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Mari KiharaDepartment of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan. kihara.rheu@tmd.ac.jp.ORCID http://orcid.org/0000-0001-7120-5693
Takahiko SugiharaGraduate School of Medical and Dental Science, Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan.
Junichi AsanoPharmaceuticals and Medical Devices Agency, Office of New Drug IV, Tokyo, Japan.
Midori SatoDepartment of Respiratory Medicine, National Hospital Organization Tokyo Medical Centre, Tokyo, Japan.
Hiroshi KanekoDivision of Rheumatic Disease, National Centre for Global Health and Medicine, Tokyo, Japan.
Sei MuraokaDepartment of Internal Medicine, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Tokyo, Japan.
Shiro OhshimaDepartment of Clinical Research, National Hospital Organization Osaka Minami Medical Centre, Kawachinagano, Japan.
Toshihiro NankiDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.
Tokyo Medical and Dental University · JPEbara Hospital · JPNational Center for Global Health and Medicine · JPNational Hospital Organization · JPOsaka Minami Medical Center · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo describe clinical characteristics of patients in Japan with coronavirus disease 19 (COVID-19) and pre-existing rheumatic disease and examine the possible risk factors associated with severe COVID-19.

methodsAdults with rheumatic disease and a COVID-19 diagnosis who were registered in the COVID-19 Global Rheumatology Alliance (C19-GRA) physician-reported registry from Japan between 15 May 2020 and 12 May 2021 were included. Multivariable logistic regression models were used to assess factors associated with severe COVID-19 progression, defined as death or requiring oxygen inhalation.

resultsIn total, 222 patients were included in the study. Rheumatoid arthritis (48.2%), gout (14.4%), and systemic lupus erythematosus (8.1%) were the most common types of rheumatic disease, 55.1% of patients were in remission and 66.2% had comorbid disease. Most patients were hospitalised (86.9%) for COVID-19, 43.3% received oxygen, and 9.0% died. Older age (≥ 65 years), corticosteroid use, comorbid diabetes, and lung diseases are associated with higher risk for severe COVID-19 progression (odds ratio (OR) 3.52 [95% confidence interval (CI) 1.69-7.33], OR 2.68 [95% CI 1.23-5.83], OR 3.56 [95% CI 1.42-8.88], and OR 2.59 [95% CI 1.10-6.09], respectively).

conclusionsThis study described clinical characteristics of COVID-19 patients with rheumatic diseases in Japan. Several possible risk factors for severe COVID-19 progression were suggested. Key points • Clinical characteristics of 222 adult patients in Japan with coronavirus disease 19 (COVID-19) and pre-existing rheumatic diseases were described. • Most patients were hospitalised (86.9%) for COVID-19 in Japan, 43.3% received oxygen, and 9.0% died. • The COVID-19 characteristics of patients with rheumatic diseases did not show any obvious different pattern from those of the general population in Japan. • In this study, older age (≥ 65 years), corticosteroid use, comorbid diabetes, and lung diseases are associated with higher risk for severe COVID-19 progression.

Indexed as

Antirheumatic AgentsCOVID-19Diabetes MellitusPhysiciansRheumatic DiseasesRheumatologyAdrenal Cortex HormonesAdultCOVID-19 TestingHumansJapanOxygenRegistriesSARS-CoV-2Adrenal Cortex HormonesAntirheumatic AgentsOxygenAntirheumatic agentsCoronavirus disease 2019ObservationalRheumatic diseasesRisk factors

Identifiers

PMID35974224
PMCPMC9380979
OpenAlexW4292002554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.